Eli Lilly announced a new weight loss drug Zepbound at a half-price(50%) or greater discount compared to the list price. So it can reach millions of patients without insurance coverage for the popular injection.
The company is now offering 2.5 mg and 5 mg single-dose vials of Zepbound for $399 per month and $549 per month, respectively, through its direct-to-consumer website – Less than half the list price of other incretin medicines for obesity and in line with the Zepbound savings program for non-covered individuals.
“We are excited to share that the Zepbound single-dose vials are now here, further delivering on our promise to increase the supply of Zepbound in the U.S. These new vials not only help us meet the high demand for our obesity medicine but also broaden access to patients seeking a safe and effective treatment option,” said Patrik Jonsson.
In a clinical study, the 5 mg maintenance dose helped patients achieve an average of 15% weight loss after 72 weeks of treatment and has been a powerful tool for millions of people with obesity looking to lose weight and keep it off.
Lilly has created a new self-pay pharmacy component of LillyDirect where patients with a valid, on-label prescription from the health care provider of their choice can purchase the vials. Distributing the vials via this channel ensures patients and providers can trust they are receiving genuine Lilly medicine. Eli Lilly Zepbound single-dose vials to patients will help
more people living with obesity manage this chronic condition.
Indication and Safety Warnings
Zepbound® is an injectable prescription medicine that may help adults with obesity, or with excess weight who also have weight-related medical problems, lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.
- Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines.
- It is not known if Zepbound is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products.
- It is not known if Zepbound can be used in people who have had pancreatitis.
- It is not known if Zepbound is safe and effective for use in children under 18 years of age.
Warnings
Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
- Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
- Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.
- For More.
Read More: Apple Announced iPhone 16 Launch Event On September 9.
2 thoughts on “Eli Lilly Releases New Weight Loss Drug at 50% Discount”